Paul Hastings
2015 - OncoMed Pharmaceuticals
In 2015, Paul Hastings earned a total compensation of $3.1M as Chairman, Chief Executive Officer & President at OncoMed Pharmaceuticals, a 5% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $323,113 |
|---|---|
| Option Awards | $2,213,383 |
| Salary | $516,980 |
| Total | $3,053,476 |
Hastings received $2.2M in option awards, accounting for 72% of the total pay in 2015.
Hastings also received $323.1K in non-equity incentive plan and $517K in salary.
Rankings
In 2015, Paul Hastings' compensation ranked 3,114th out of 13,638 executives tracked by ExecPay. In other words, Hastings earned more than 77.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,114 out of 13,638 | 77th |
Division Manufacturing | 1,110 out of 5,187 | 79th |
Major group Chemicals And Allied Products | 407 out of 1,857 | 78th |
Industry group Drugs | 320 out of 1,531 | 79th |
Industry Pharmaceutical Preparations | 255 out of 1,179 | 78th |
Source: SEC filing on April 13, 2017.
Hastings' colleagues
We found two more compensation records of executives who worked with Paul Hastings at OncoMed Pharmaceuticals in 2015.